Earnings presentation on unaudited results for Q1FY2027.

July 26, 2026 BSE Limited National Stock Exchange of India Limited Department of Corporate Services Listing Department, Floor 25, Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Kala Ghoda, Fort Bandra Kurla Complex, Bandra (East), Mumbai - 400 001 Mumbai – 400 051 Scrip Code No: 542665 Company Symbol: NEOGEN Debt Segment Code: 977028 Sub.: Earnings Presentation on the Unaudited Financial Results of the Company for the quarter ended June 30, 2026, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir/ Madam, With reference to the captioned subject, please find enclosed herewith the Earnings Presentation on the unaudited financial results (standalone and consolidated) of the Company for the quarter ended June 30, 2026. The Earnings Presentation is also being uploaded on the Company’s website at https://neogenchem.com/financial-performance/. Kindly take the same on your record. Thanking you, For Neogen Chemicals Limited Unnati Kanani Company Secretary and Compliance Officer Mem. No.: A35131 Encl.: As above Registered Office: 1002, Dev Corpora, Cadbury Junction, E: sales@neogenchem.com T: +91 22 2549 7300 Eastern Express Highway, Thane (W) 400 601, India. W: www.neogenchem.com F: +91 22 2549 7399 CIN No. L24200MH1989PLC050919 ‘Capitalising on Opportunities Rising in Strength’ Q1 FY27 Earnings Presentation July 2026 Safe Harbor Certain statements in this document may be forward-looking statements. Such forward looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Neogen Chemicals Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances. Table of Contents 01 02 03 01 02 03 Q1 FY27 Financial Introduction to Industry Overview: Performance & Neogen Chemicals Lithium-Ion Batteries Expansion Initiatives 04 05 06 04 05 06 Way Forward Sustainability & Contact Us CSR Initiatives Q1 FY27 Financial Performance & Expansion Initiatives Performance Highlights – Q1 FY27 Q1 FY27 Revenue break-up** INR in crore Standalone Consolidated Revenues 37% 252 34% 250 30% Domestic *Exports Gross Profit 31 % 109 37% 117 *Including deemed exports EBITDA 39% 48 53% 48 57 23% PAT 37% 19 67% 17 194 77% Q1 FY26 Q1 FY27 Organic Inorganic **Consolidated figures Note: Growth for Q1 FY27 is compared to Q1 FY26. 5 Financial Summary – Q1 FY27 Standalone Consolidated Standalone Consolidated Standalone Consolidated REVENUE EBITDA PAT INR in crore INR in crore INR in crore 252 250 48 48 19 185 187 35 32 14 10 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 ● Strong growth despite the temporary Dahej ● Robust EBITDA despite ongoing global ● PAT trajectory reflected strong underlying plant shut down. Managed by efficient headwinds; cost pass-throughs initiated for operating trends, partly moderated by higher management of toll manufacturing sites RM and input costs (freight, packaging, finance costs (up 64% Y-o-Y) utilities, etc.) to protect operating margins ● Revenue expansion anchored by higher ● Increased interest burden driven by: volumes for key product lines ● Performance was bolstered by favorable o Higher debt drawdown to fund product mix, achieving highest-ever quarterly ● Organolithium Portfolio delivered robust ongoing CAPEX revenues in both Organolithium and Battery gains driven by enhanced plant throughput o Increased working capital intensity Chemicals, alongside strong volume growth ● Neogen Ionics (NIL): Q1 FY27 revenue in Inorganic Chemicals. This was achieved driven by geopolitical supply chain reached INR 19 crore (vs. INR 5 crore in Q1 despite headwinds from higher costs, inflation FY26) including temporary expenses related to the o Delay in insurance receipts Dahej plant rebuild, toll manufacturing, expansion overheads at NIL, and geopolitical freight spikes Financial Table – Profit & Loss Statement (Standalone) Particulars (INR In crore) Q1 FY27 Q1 FY26 Growth (%) Revenue 252.3 184.6 37% Expenditure 204.1 149.9 36% EBITDA 48.2 34.7 39% EBITDA Margins 19.1% 18.8% +30 bps Depreciation 6.8 4.9 40% Other Income 7.9 3.3 139% EBIT (inc. Other Income) 49.2 33.1 49% Interest 23.1 14.0 65% Profit Before Tax 26.1 19.1 37% PBT Margins 10.4% 10.3% +10 bps Exceptional Items 0.0 0.0 NA Profit Before Tax (inc. exceptional items) 26.1 19.1 37% Tax Expense 6.7 4.9 38% Profit After Tax 19.4 14.2 37% PAT Margins 7.7% 7.7% - Earnings Per Share (INR) *7.15 *5.40 32% * Not annualized Financial Table – Profit & Loss Statement (Consolidated) Particulars (INR In crore) Q1 FY27 Q1 FY26 Growth (%) Revenue 250.3 186.7 34% Expenditure 202.1 155.2 30% EBITDA 48.2 31.5 53% EBITDA Margins 19.3% 16.9% +260 bps Depreciation 8.2 5.8 42% Other Income 3.9 1.2 227% EBIT (inc. Other Income) 43.9 26.9 63% Interest 20.8 12.7 64% Profit Before Tax (including share of profit) 23.3 14.3 63% PBT Margins 9.3% 7.7% +160 bps Exceptional Items 0.0 0.0 NA Profit Before Tax (inc. exceptional items) 23.3 14.3 63% Tax Expense 6.2 4.0 53% Profit After Tax 17.1 10.3 67% PAT Margins 6.8% 5.5% +130 bps Earnings Per Share (INR) *6.29 *3.89 62% * Not annualized Key Updates – Q1 FY27 (Neogen Chemicals) Update on Dahej Fire Incident • Cumulative recoveries stand at INR 164 crore to date, comprising INR 155 crore in on-account insurance claims (including a recent tranche of INR 15 crore in July 2026) and INR 9 crore from salvage realization and has incurred further incidental charges of INR 1 crore which is also claimed as per insurance policy upto June 30, 2026. o Net claim receivable as on date stands at INR 186 crore on consolidated basis • Reconstruction of the Dahej plant is complete, with trial runs underway; commercial production to begin soon Board Approval for Fund Raise • The Board has approved raising up to INR 600 Crore (in INR or foreign currency) through issue of eligible securities, by way of a Qualified Institutional Placement (QIP), subject to necessary shareholder and statutory approval Update on various expansion initiatives Neogen Ionics Proposed Manufacturing Setup Manufacturing locations Land Area Year Planned Capacities Electrolyte Lithium Electrolyte Salts & Additives FY25 2,000 MT 400 MT Dahej SEZ 6,455 m2 FY26 - 1,100 MT FY27 - 1,000 MT Pakhajan, Dahej PCPIR (New site) 264,285 m2 FY27 30,000 MT 3,000 MT Total 270,740 m2 32,000 MT 5,500 MT Battery Chemicals Business Details of expansion projects announced Current project updates Capacity of 1,500 MTPA for manufacturing ● 200 MTPA commissioned; first approval material shipped to the customers Lithium Electrolyte Salts and additives ● For remaining 1,300 MTPA, trial production ongoing Lithium Electrolyte Salts Plant for manufacturing 2,000 MT of Electrolyte Electrolytes ● 2,000 MT fully commissioned in FY25 at Dahej facility New Capacity of 1,000 MTPA for manufacturing ● 1,000 MT to be commissioned by H2 FY27 Lithium Electrolyte Salts and Additives ● 500 MT additional intermediate to be commissioned in H2 FY27 Update on Battery Chemicals (Neogen Ionics) Execution Roadmap & CAPEX Project Updates • Total estimated project cost for Neogen Ionics’ Dahej Phase 1 and • Project completion timelines remain on schedule for Electrolytes (H1 FY27) Pakhajan Phase 2 Battery Materials projects stands at INR 1,795 crore and Electrolyte Salts (H2 FY27) (INR 218 crore incurred in Q1 FY27; cumulative INR 1,298 crore to date) • Electrolyte: Mechanical assembly complete and trial runs initiated; facility o Dahej Phase 1 project cost stands at INR 428 crore with target validation and product approvals by leading domestic battery manufacturers completion by February 2027, while P [Showing first 8,000 characters — download PDF for full document]